Core Viewpoint - The A-share market shows strong momentum entering 2026, with the pharmaceutical sector rebounding significantly, as evidenced by the 7.81% increase in the pharmaceutical and biotechnology index in just five trading days [1][23]. Group 1: Fund Performance - The E Fund Healthcare Fund has outperformed the industry index with a net value increase of 16.85% in the same period [1][23]. - Since manager Yang Zhenshao took over in August 2016, the fund has achieved a return of 237.49% and an annualized return of 13.81% [1][23]. - The fund has consistently outperformed the pharmaceutical and biotechnology index for nine consecutive years since 2017, demonstrating the manager's value [1][23]. Group 2: Investment Strategy - Yang Zhenshao's investment approach combines macro and micro perspectives, focusing on industry cycle positions and trends while pursuing long-term alpha through bottom-up balanced allocation [26][30]. - The fund maintains a high stock position, typically over 92%, with a relatively low turnover rate, indicating a long-term investment style [27][28]. - The strategy emphasizes the importance of deep research to support long-term holdings, which helps avoid excessive trading and capitalizes on systematic industry growth opportunities [28][30]. Group 3: Market Trends and Opportunities - Yang Zhenshao is keenly aware of new industry trends, having positioned the fund in advance of the recent surge in innovative drugs, which has contributed to the fund's strong performance [30][34]. - The pharmaceutical index has shown a significant long-term growth of 1090.57% over the past 20 years, far exceeding the 401.52% growth of the CSI 300 index [30][31]. - The current focus is on the innovative drug sector, which is expected to recover in liquidity, providing attractive opportunities for quality asset allocation [40][42]. Group 4: Future Outlook - The strategy remains to pursue stable excess returns while dynamically adjusting allocation ratios based on the economic conditions of various pharmaceutical sub-sectors [39][40]. - The launch of the new E Fund Hong Kong Stock Connect Healthcare Mixed Fund aims to capture the global benefits of China's pharmaceutical innovation [43][44]. - Yang Zhenshao's proven track record and deep research background position him as a valuable asset in navigating the evolving pharmaceutical investment landscape [44].

Core Viewpoint - The innovative drug sector has shown a strong recovery since the beginning of 2026, with increased attention and investment opportunities due to a surge in small nucleic acid listings and ongoing international business development transactions, reflecting global recognition of Chinese innovative drugs [1][7]. Group 1: Investment Timing and Strategy - The Longcheng Pharmaceutical Industry Selected Fund was established in October 2024, shortly after a strong market rebound, which initially affected performance due to market volatility [1][4]. - The fund manager identified the innovative drug sector as having long-term growth potential and value realization opportunities, especially following significant policy shifts that improved the industry environment [1][4]. Group 2: Factors for Sector Layout and Stock Selection - Key considerations for sector layout include the growth potential and development space of the industry, as well as identifying listed companies that can benefit from industry opportunities [1][4]. - The stock selection process involves a "three-cycle framework" focusing on supply-demand cycles, company fundamentals, and capital market cycles to determine stock positions [1][4]. Group 3: Investment Strategy - The investment strategy employs a "three-cycle resonance" approach, seeking companies that align with industry, company growth, and capital market cycles [2][5]. - The focus is on capturing profits from rapid company earnings growth and recognizing valuation expansion potential in companies with "explosive product" logic [2][5]. Group 4: Market Outlook for 2026 - The innovative drug sector is expected to continue performing well in 2026, particularly in the first half, although the difficulty of market timing and stock selection will increase compared to 2025 [3][6]. - The fund manager remains highly focused on innovative drugs, anticipating that certain stocks will gradually realize returns as they reach target market values over the next 1-2 years [3][6].

Core Viewpoint - The company, Anhui Huaren Health Pharmaceutical Co., Ltd., has shown significant growth in its stock performance and business operations, particularly in the pharmaceutical e-commerce and elderly health sectors, with a notable increase in revenue and net profit. Group 1: Stock Performance - On January 14, Huaren Health's stock reached its daily limit, with a trading volume of 2.207 billion yuan and a turnover rate of 54.39%, resulting in a total market capitalization of 11.904 billion yuan [1] - The stock has seen a net inflow of 52.9871 million yuan today, with a total of 2.17 billion yuan over the last three days, indicating a positive trend in investor interest [5] Group 2: Business Operations - The company has established a presence on major e-commerce platforms, including JD.com, Pinduoduo, and Meituan, in addition to Alibaba's Tmall and Ele.me, achieving significant growth during the reporting period [2] - Huaren Health is actively developing products targeting the elderly health market, focusing on chronic disease management and offering a range of health products tailored to the needs of older adults [2][3] - The company has a strong pipeline of 22 research and development projects focused on innovative and high-end generic drugs, emphasizing its commitment to the pharmaceutical health sector [3] Group 3: Financial Performance - For the period from January to September 2025, Huaren Health reported a revenue of 3.892 billion yuan, representing a year-on-year growth of 19.06%, and a net profit attributable to shareholders of 157 million yuan, up 45.21% year-on-year [8] - The company has distributed a total of 80.02 million yuan in dividends since its A-share listing [9] Group 4: Shareholder Structure - As of September 30, 2025, the number of shareholders in Huaren Health was 20,100, a decrease of 22.86% from the previous period, with an average of 7,422 circulating shares per person, an increase of 29.64% [8] - Hong Kong Central Clearing Limited is the fifth-largest circulating shareholder, holding 2.3203 million shares, an increase of 1.3357 million shares compared to the previous period [9]

Group 1: Grid Trading Strategy Overview - The essence of "grid trading" is a high buy low sell strategy, which does not predict market trends but utilizes natural price fluctuations within a certain range to generate profits, suitable for frequently fluctuating markets [4][13] - Characteristics of suitable grid trading targets include: selecting on-market targets, stable long-term trends, low trading costs, good liquidity, and high volatility. Equity ETFs are considered relatively suitable for grid trading [4][13] Group 2: ETF Grid Strategy Target Analysis - **Hang Seng Medicine ETF (159892.SZ)**: Benefiting from the Federal Reserve's interest rate cut cycle, which improves the financing environment for innovative drugs. China's innovative drugs are accelerating their globalization, becoming a core driver for commercialization. As of January 4, 2026, China's new drug pipeline accounts for about 30% of the global total, ranking second worldwide. In 2025, 76 innovative drugs were approved for marketing in China, with domestic innovative drugs accounting for 80.85% of chemical drugs and 91.30% of biological products [4][14] - **Brokerage ETF (159842.SZ)**: High market activity catalyzes the release of brokerage performance, with capital market reforms opening up long-term growth space for leading brokerages. The Shanghai Composite Index rose from a low of 3040 points to break through 4000 points, with an annual increase of 18.41%. The total A-share trading volume reached 420.21 trillion yuan, a year-on-year increase of 62.64% [5][17] - **New Economy ETF (159822.SZ)**: A one-stop layout for high-quality new economy leading enterprises in China, capturing the key to economic transformation. The ETF indirectly tracks the S&P China New Economy Industry Index, holding leading companies in artificial intelligence, internet, biotechnology, and innovative drugs, which are high-growth sectors [6][19] - **Coal ETF (515220.SH)**: Benefiting from the "anti-involution" policy and dividend investment logic. The central economic work conference in December 2025 identified "deepening the rectification of 'involutionary' competition" as a key task for 2026, which is expected to control new capacity and improve the coal industry's supply-demand fundamentals. As of January 13, 2026, the coal sector's dividend yield reached 5.52%, significantly higher than the market average and the yield on ten-year government bonds [7][22]

Core Viewpoint - The article discusses various ETF grid strategies focusing on sectors such as pharmaceuticals, biotechnology, and coal, highlighting their potential for investment based on market trends and economic policies. Group 1: Pharmaceutical Sector - The Hang Seng Pharmaceutical ETF (159892.5Z) is expected to benefit from the Federal Reserve's interest rate cut cycle, which may lower financing costs for pharmaceutical companies, thereby enhancing their R&D capabilities [3][4]. - As of January 2026, China holds approximately 30% of the global new drug pipeline, ranking second worldwide. In 2025, 76 innovative drugs were approved in China, with domestic innovations accounting for 80.85% of chemical drugs and 91.30% of biological products [3][4]. - The total value of innovative drug licensing transactions in China exceeded $130 billion in 2025, with over 150 deals, indicating a significant enhancement in China's innovative drug capabilities and acceleration in globalization [3][4]. Group 2: Brokerage Sector - The Brokerage ETF (159842.5Z) reflects a strong performance in 2025, with the Shanghai Composite Index rising from a low of 3040 points to over 4000 points, marking an annual increase of 18.41%. The total trading volume in A-shares reached 420.21 trillion yuan, a year-on-year growth of 62.64% [7][8]. - By the end of 2025, the financing balance in A-shares exceeded 2.52 trillion yuan, growing over 36% compared to the end of 2024, indicating a robust expansion in market activity [7][8]. - The ongoing reforms in the capital market are expected to enhance the efficiency of capital utilization among leading brokerages, thereby expanding their growth potential [8]. Group 3: New Economy Sector - The New Economy ETF (159822.SZ) aims to track the S&P China New Economy Index, focusing on high-growth sectors such as artificial intelligence, internet, biotechnology, and innovative pharmaceuticals, which are crucial for capturing new economic growth drivers in China [11]. Group 4: Coal Sector - The Coal ETF (515220.SH) is positioned to benefit from the central economic work conference's focus on controlling new capacity and improving the coal industry's supply-demand fundamentals, which may enhance profitability [15]. - As of January 2026, the coal sector's dividend yield reached 5.52%, significantly higher than the market average and the yield on ten-year government bonds, indicating strong investment value in the medium to long term [15].

Core Viewpoint - The A-share market experienced an overall adjustment, with significant trading activity continuing, particularly in the AI application and pharmaceutical sectors, while the commercial aerospace sector faced a notable decline [1][2][3]. Group 1: Market Performance - The Shanghai Composite Index closed at 4138.76 points, down 0.64%, while the Shenzhen Component Index fell 1.37% to 14169.40 points. The ChiNext Index and the Sci-Tech Innovation Board Index also saw declines of 1.96% and 2.66%, respectively [1]. - The total trading volume in the Shanghai and Shenzhen markets reached 36,988 billion yuan, marking the third consecutive trading day exceeding 30 trillion yuan, setting a new record for single-day trading volume in A-shares [1]. Group 2: Sector Performance - The AI application sector remained active, with the GEO (Generative Engine Optimization) direction leading gains. Notable stocks included Ingrity Media, which achieved six consecutive trading limits, and Tianlong Group and Lio Co., which saw three consecutive trading limits [1]. - The pharmaceutical sector collectively rose, with AI medical, innovative drugs, and CRO (Contract Research Organization) sectors showing strong performance. Stocks like Nossger and Rongchang Bio reached their daily limit of 20% [3][4]. Group 3: Pharmaceutical Sector Developments - Pharmaceutical companies are experiencing multiple favorable factors, including positive earnings forecasts from leading companies. WuXi AppTec projected a net profit of approximately 19.15 billion yuan for 2025, representing a year-on-year increase of about 102.65% [4]. - Rongchang Bio announced a significant business development agreement with AbbVie for its new PD-1/VEGF dual-specific antibody drug, RC148, which includes an upfront payment of 650 million USD and potential milestone payments up to 4.95 billion USD [4]. - The establishment of a new AI joint innovation laboratory by NVIDIA and Eli Lilly in the San Francisco Bay Area, with an investment of up to 1 billion USD over five years, aims to enhance drug discovery and development processes [4]. Group 4: Commercial Aerospace Sector - The commercial aerospace sector faced a significant pullback, with stocks like Aerospace Hanyu and Aerospace Software dropping over 10%, and several stocks hitting their daily limit down [2]. - Chinese Satellite's stock experienced a daily fluctuation of 19.53%, closing up 4.17%, with a trading volume of 22.74 billion yuan, ranking fourth in A-shares [2]. Group 5: Market Outlook - Analysts suggest that the market is in a critical window for policy catalysis and industrial rotation, with structural trends continuing but increasing differentiation. The market is expected to maintain a slow upward trend supported by policy and industrial upgrades [7][8]. - The pharmaceutical and resource sectors are anticipated to be core investment themes for 2026, with frequent sector rotation and style switching expected [8].

Core Viewpoint - The company, Shenzhen Hepalink Pharmaceutical Group Co., Ltd., is a leading multinational pharmaceutical enterprise with a focus on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development, benefiting from the depreciation of the RMB and a significant overseas revenue share [2][3]. Company Overview - Shenzhen Hepalink was established in 1998 and has dual financing platforms (A+H shares) [2]. - The main business segments include heparin sodium raw materials, low molecular weight heparin products, and CDMO services, with revenue contributions of 63.06% from formulations, 18.59% from CDMO, and 16.05% from heparin products [7]. - As of September 30, 2025, the company reported a revenue of 4.194 billion yuan, a year-on-year increase of 3.09%, while net profit decreased by 29.04% to 554 million yuan [7]. Financial Performance - The company’s overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the RMB [3]. - The total market capitalization is 18.048 billion yuan, with a trading volume of 87.8751 million yuan and a turnover rate of 0.57% [1]. Shareholder Information - As of September 30, 2025, the number of shareholders increased to 27,000, with an average of 0 circulating shares per person [7]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 12.0093 million shares, an increase of 691,700 shares from the previous period [9]. Technical Analysis - The average trading cost of the stock is 11.62 yuan, with the current price approaching a resistance level of 12.37 yuan, indicating potential for upward movement if the resistance is broken [6].

Group 1 - The economic and financial cycles are currently in a phase of upward resonance, with the second inventory cycle entering a proactive replenishment stage, likely transitioning to a destocking phase in major economies by 2026 [11] - The recommended asset allocation for 2026 is A-shares > Chinese bonds, US bonds > US stocks, as the stabilization of overall A-share corporate earnings supports further recovery [11] - The cumulative profit growth for all A non-financial companies in 2025 is expected to be in the range of 2.4%-5.5%, indicating a continued trend of profit recovery that will underpin the upward movement of the equity market [15][16] Group 2 - The current A-share environment is compared to the 2013-2014 period, highlighting similarities in macroeconomic conditions and structural trends, with a focus on technology and consumption sectors [27] - The technology sector is expected to continue contributing significant profit increments, particularly in the AI industry chain, which remains robust in demand [45] - The report suggests focusing on sectors such as electronics, media, innovative pharmaceuticals, non-ferrous metals, and new energy, which are expected to outperform in 2026 due to various driving factors [48]

Group 1 - The pharmaceutical and biotechnology industry is experiencing a sustained improvement in prosperity, with innovative drugs entering the 3.0 era, showcasing a leading trend in new targets, technologies, and disease areas in China [1] - Recent positive clinical data for small nucleic acid drugs and the emergence of targeted delivery technologies indicate significant potential in chronic disease areas such as cardiovascular and metabolic diseases [1] - The domestic CRO (Contract Research Organization) orders are showing a trend of increasing volume and price, benefiting from the overseas business development of innovative drugs and a stabilization in financing, with performance expected to improve by 2026 [1] Group 2 - The medical device industry continues to have demand-side potential, with supply-side structural upgrades and accelerated innovation and internationalization, expected to maintain steady growth through 2026 [1] - The exploration of AI in medicine is ongoing, with potential effective business models emerging in areas such as assisted diagnosis and health management [1] - Brain-computer interface technology is undergoing rapid iteration and upgrades, with significant clinical and commercialization advancements anticipated by 2026, marking a new development phase for the industry [1] Group 3 - The vaccine ETF (159643) tracks the vaccine biotechnology index (980015), which selects listed companies involved in vaccine research, production, and related biotechnology businesses to reflect the overall performance of the biopharmaceutical and research service sectors [1] - This index is characterized by high growth and innovation, focusing on the bioproducts and research service fields [1]

Core Viewpoint - Lingrui Pharmaceutical's stock has experienced a decline recently, with a slight increase in revenue and net profit year-on-year, indicating potential challenges in market performance despite positive financial growth [1][2]. Group 1: Stock Performance - On January 14, Lingrui Pharmaceutical's stock fell by 2.03%, trading at 20.73 CNY per share, with a total market capitalization of 11.756 billion CNY [1]. - The stock has seen a year-to-date increase of 0.10%, but has declined by 3.36% over the last five trading days, 2.63% over the last 20 days, and 10.03% over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Lingrui Pharmaceutical achieved a revenue of 3.041 billion CNY, representing a year-on-year growth of 10.23% [2]. - The net profit attributable to shareholders for the same period was 651 million CNY, reflecting a year-on-year increase of 13.43% [2]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Lingrui Pharmaceutical increased to 42,500, a rise of 25.64% compared to the previous period [2]. - The average number of circulating shares per shareholder decreased by 20.41% to 13,307 shares [2]. - The company has distributed a total of 2.544 billion CNY in dividends since its A-share listing, with 1.3 billion CNY distributed over the last three years [3].